DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020527/S-051
NDA 020527/S-052
NDA 020527/S-054
NDA 020527/S-056

SUPPLEMENT APPROVAL

Wyeth Pharmaceuticals, Inc.
c/o Pfizer Inc.
Attention: Ursula Campbell
Senior Director, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Campbell:

Please refer to your Supplemental New Drug Applications (sNDAs) dated October 9, 2009, for S-051; November 30, 2009, for S-052; March 15, 2010, for S-054; and November 9, 2010, for S-056 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PREMPRO® (conjugated estrogens/medroxyprogesterone acetate tablets) and PREMPHASE® (conjugated estrogens plus medroxyprogesterone acetate tablets).

We acknowledge receipt of your amendments dated March 2, March 16, and October 27, 2010, and February 10, August 12, and September 12, 2011.

These supplemental new drug applications, as amended, provide for the following:

- Addition of two new CONTRAINDICATIONS of known anaphylactic reaction or angioedema and known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
- Addition of two new WARNINGS AND PRECAUTIONS of anaphylactic reaction and angioedema and hereditary angioedema
- Updates to the ADVERSE REACTIONS section to reflect treatment related adverse reactions and the addition of the terms “ischemic colitis” and “growth potentiation of benign meningioma” to the Postmarketing Experience section
- Revisions to selected sections of the Prescribing Information to reflect current recommended estrogen-class labeling
- Modifications to pertinent sections of labeling to reflect reformulation of the 0.625mg/5mg tablet
- Revisions to selected sections of Patient Package Insert to reflect changes in the Prescribing Information including the addition of have been diagnosed with a bleeding disorder

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials

should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim Shiley, R.N., B.S.N., Regulatory Health Project Manager, at (301) 796-2117
.

Sincerely,

{See appended electronic signature page}

Christine P. Nguyen, M.D.
Acting Deputy Director for Safety
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
02/02/2012